About the Safety Working Group

Harms provide important context for healthcare practitioners about the benefit-risk ratio of interventions. To improve transparency and credibility in the published results from randomized trials, the reporting of harms associated with an intervention needs to be explicit regarding what is patient-important, which may be different from that reported by clinicians submitting adverse event reports

Following the concerns about inadequate reporting of harm outcomes in randomized trials and systematic reviews the Outcome Measures in Rheumatology (OMERACT) Safety Working Group is advancing the work to identify additional harm aspects for assessment in rheumatology trials

Peter Brooks

Peter Brooks

Co-Chair

Robin Christensen

Robin Christensen

Co-Chair

Caroline Flurey

Caroline Flurey

Co-Chair

Lee Simon

Lee Simon

Co-Chair

dorthe

Dorthe B. Berthelsen

Marieke Scholte-Voshaar

Marieke Scholte-Voshaar

How patients can help the Safety Working Group to improve reporting of side effects from rheumatological medications.

If you want to know more, please contact: [email protected]

Working Group Members:

Maarten Boers
Peter Brooks
Robin Christensen
Daniel Devoe
Daniel Furst
Niti Goel
Susan Goodman
Glen Hazelwood
Orit Schieir
Vivian Bykerk
Bev Shea
Lyn March
Karina Torralba
Charlotte Bekker

Catherine Hill
Amye Leong
Sarah Mackie
Pam Richards
Marieke Scholte-Voshaar
Lee Simon
Dorthe Berthelsen
Caroline Flurey
Dorcas Beaton
Lara Maxwell
Salome Kristensen
Tanja Schjødt Jørgensen

Vibeke Strand
Maria Suarez-Almazor
Peter Tugwell
Paula Williamson
Thasia Woodworth
Jasvinder Singh
Elisabeth Ginnerup Læbo
Susan Bartlett
Sabrina M Nielsen
Marianne U. Rasmussen
Torkell Ellingsen
Samar Tharwat Radwan

Interested in joining the working group as a member?

Please enter your name.
Please enter a message.
Scroll to Top